AUX-002

AUX-002 is a preclinical-stage drug candidate being developed by Auxilius Pharma for the treatment of cardiovascular diseases. The drug is currently in the formulation stage and is being developed via the FDA's 505(b)(2) regulatory pathway, which suggests it is a new formulation, dosage form, or repositioned version of an existing active pharmaceutical ingredient. Auxilius Pharma focuses on creating value-added medications by optimizing well-established drugs for markets where they are currently unavailable or where unmet clinical needs exist. As of 2024, specific details regarding the active ingredient, molecular target, and precise therapeutic indication within the cardiovascular field have not been publicly disclosed.